Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatment.
Reich K, Augustin M, Thaçi D, Pinter A, Leutz A, Henneges C, Schneider E, Schacht A, Dossenbach M, Mrowietz U. Reich K, et al. Among authors: henneges c. Br J Dermatol. 2020 Apr;182(4):869-879. doi: 10.1111/bjd.18384. Epub 2019 Nov 19. Br J Dermatol. 2020. PMID: 31376153 Free PMC article. Clinical Trial.
Prevalence of genital psoriasis in patients with psoriasis.
Meeuwis KAP, Potts Bleakman A, van de Kerkhof PCM, Dutronc Y, Henneges C, Kornberg LJ, Menter A. Meeuwis KAP, et al. Among authors: henneges c. J Dermatolog Treat. 2018 Dec;29(8):754-760. doi: 10.1080/09546634.2018.1453125. Epub 2018 Mar 28. J Dermatolog Treat. 2018. PMID: 29565190 Free article. Review.
Impact of Ixekizumab Treatment on Itch and Psoriasis Area and Severity Index in Patients with Moderate-to-Severe Plaque Psoriasis: An Integrated Analysis of Two Phase III Randomized Studies.
Yosipovitch G, Reich A, Steinhoff M, Beselin A, Kent T, Dossenbach M, Berggren L, Henneges C, Luger T. Yosipovitch G, et al. Among authors: henneges c. Dermatol Ther (Heidelb). 2018 Dec;8(4):621-637. doi: 10.1007/s13555-018-0267-9. Epub 2018 Nov 21. Dermatol Ther (Heidelb). 2018. PMID: 30465321 Free PMC article. Review.
Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia.
Casabé A, Roehrborn CG, Da Pozzo LF, Zepeda S, Henderson RJ, Sorsaburu S, Henneges C, Wong DG, Viktrup L. Casabé A, et al. Among authors: henneges c. J Urol. 2014 Mar;191(3):727-33. doi: 10.1016/j.juro.2013.09.059. Epub 2013 Oct 2. J Urol. 2014. PMID: 24096118 Clinical Trial.
Treatment satisfaction and clinically meaningful symptom improvement in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: Secondary results from a 6-month, randomized, double-blind study comparing finasteride plus tadalafil with finasteride plus placebo.
Roehrborn CG, Casabé A, Glina S, Sorsaburu S, Henneges C, Viktrup L. Roehrborn CG, et al. Among authors: henneges c. Int J Urol. 2015 Jun;22(6):582-7. doi: 10.1111/iju.12741. Epub 2015 Mar 31. Int J Urol. 2015. PMID: 25827166 Clinical Trial.
Effects of tadalafil treatment after bilateral nerve-sparing radical prostatectomy: quality of life, psychosocial outcomes, and treatment satisfaction results from a randomized, placebo-controlled phase IV study.
Patel HR, Ilo D, Shah N, Cuzin B, Chadwick D, Andrianne R, Henneges C, Barry J, Hell-Momeni K, Branicka J, Büttner H. Patel HR, et al. Among authors: henneges c. BMC Urol. 2015 Apr 12;15:31. doi: 10.1186/s12894-015-0022-9. BMC Urol. 2015. PMID: 25879460 Free PMC article. Clinical Trial.
46 results